他のページへ 更新情報 日本の石油化学 その他化学・周辺業界 アジアの石油化学 |
Bayer Lanxessへ
"The New Bayer" 2003/4/25
渦中の医薬継続 香料メーカーHaarmann & Reimer売却 Rhein Chemie売却→ 取り止め
Bayer CropScience AG to sell a range of products to BASF 売却完了
Degussa and Bayer sell PolymerLatex to Soros Private Equity Partners
Bayer Plans to Invest in the Construction of a HDI Project in Shanghai
Bayer CropScience Intends to Overtake Syngenta
2001/11 バイエル、上海近郊の新生産基地に関する基本契約に調印
Groundbreaking ceremony for a new polycarbonate plant at Caojing, Shanghai
2006/9 Bayer CEO Wenning at the inauguration of new production facilities in Shanghai
World-scale PBT plant by DuBay Polymer GmbH (jv of DuPont and Bayer)
NewCo to be named "LANXESS" 「ランクセス」
「動き出す」という意味のフランス語『lancer』と
「成功」という意味の英語『success』を組み合わせたものBayer CropScience to purchase Crompton's share of Gustafson seed treatment business
Bayer:Agreement signed to build a plant for the coating raw material HDI in China
Bayer MaterialScience Builds New Production Facilities in China
2004/7 LANXESS starts operating independently
Bayer to Acquire Roche Consumer Health
バイエル社とシェリング・プラウ社、医療用医薬品事業で戦略的業務提携に合意
Lanxess to be spun off to stockholders
Bayer sets allotment ratio for Lanxess shares at 10 to 1
Stockholders approve the spin-off of Lanxess
LANXESS sees itself as an independent company that is well-positioned for the future
Lanxess closes rubber, fiber plants at Marl, Goch, Germany
バイエル社、血漿分画製剤事業を米国投資会社 Cerberus社とAmpersand社に売却
2004/12 帝人化成と独バイエル、ＰＣ相互供給
バイエル、2008年までに日本に1億3,000万ユーロ以上を投資
Bayer MaterialScience develops pioneering technology for the production of TDI
Bayer divests holding in GE Bayer Silicones
Bayer MaterialScience to acquire Taiwan’s Ure-Tech Group （台湾優得）
Bayer sells H.C. Starck to Advent International and The Carlyle Group for EUR 1.2 billion
Bayer invests Eur 80 mil for PC in China and India
Bayer MaterialScience closes MDI Facility at New Martinsville, W.Va., USA
Bayer MaterialScience expands MDI production capacity in Tarragona to 150,000 tons a year
Dow to Acquire Wolff Walsrode from Bayer
Bayer establishes a polyurethane spray competency center in Shanghai
Bayer Schering Pharma AG acquires U.S. Biologics manufacturing facility from Novartis
Bayer CropScience to acquire US cotton seed company Stoneville from Monsanto
Bayer keen on consumer health buys
Bayer in spotlight after Sabic's GE Plastics buy
Bayer MaterialScience to build up a world-scale plant for polymer polyols using a new technology
Bayer May Further Delay Chinese Polycarbonate Project
Bayer MaterialScience is to transfer EXATEC shares to GE Plastics
Bayer Expansion of the global compounding network
Bayer expanded Carbon nanotube capacity
Bayer makes Indonesia Asia-Pacific production base of OTC drugs
Bayer MaterialScience examines feasibility of 400,000-ton MDI plant in Europe
Bayer MaterialScience to build a world-scale plant for polymer polyols in Antwerp
Bayer sites searched by German Cartel Office in competition probe
Bayer may announce plastics restructuring
Bayer launches Group-wide climate program
Dow to use Bayer's IMPACT technology to make polyols
Bayer has financial means for 'larger' acquisition - CEO
| バイエルＡＧ（Ｂａｙｅｒ
ＡＧ） １８６３年 フリードリヒ・バイエル社設立 １８９９年 アスピリン誕生 １９２５年設立のイー・ゲー・ファルベンインドゥストリー社に吸収される。 第２次大戦後 イー・ゲー・ファルベンインドゥストリー社解体 ９５年末 米モンサント社のＡＢＳ樹脂事業を５億８，０００万ドルで買収 タイ PC Construction of Bayer's isocyanate
production base in Shanghai |
Polymers子会社とChemical子会社の一部事業を統合し新会社設立予定
米国の体制
Miles' switch to
Bayer adds to global identity
http://waw.wardsauto.com/ar/auto_miles_switch_bayer/
The Miles-to-Bayer switch comes five months after Miles acquires Sterling Withrop's North American over-the-counter drug business, including Bayer aspirin and the Bayer trademark.
Products http://www.bayer.com/en/tk/polymers.php
Bayer's Polymers segment
comprises five business groups: Plastics, Rubber, Polyurethanes,
Coatings and Colorants, including the subsidiaries Bayer Faser
GmbH (fibers).
Plastics
The Plastics Business Group supplies a broad range of engineering thermoplastics and high-tech semifinished products to meet the differing requirements of a wide variety of industries.
Films Makrofol / Bayfol PC / PC-Blends Polyamides and Polyesters Durethan A PA 66 Durethan B + T PA 6 Pocan PBT / PET Polycarbonates Apec PC-HT Makrolon PC Styrenics Bayblend PC+ABS Lustran ABS ABS Lustran SAN SAN Novodur ABS ABS Triax ABS+PA Thermoplastic Polyurethanes Desmopan TPU
Rubber
As a leading supplier of raw materials, Bayer is among the most important partners to the rubber and tire industry. The portfolio of the Rubber Business Group comprises synthetic rubber, rubber chemicals and modifiers for the plastics industry, along with special preparations and processing chemicals from Bayer subsidiary RheinChemie and latices from PolymerLatex, a joint venture with Degussa-Huls AG.
Tradename Chemical Description Abbreviation Bayer Bromobutyl Bromobutyl rubber BIIR Bayer Butyl Butyl rubber IIR Bayer Chlorobutyl Chlorobutyl rubber CIIR Baypren® Chloroprene rubber CR Buna® BL Styrene-butadiene diblock copolymers SB Buna® CB Butadiene rubber for plastic modification BR Buna® EP Ethylene-propylene rubber EPM/EPDM Buna® SL Solution styrene-butadiene rubber S-SBR Buna® VSL Solution vinyl-butadiene-styrene-butadiene rubber S-VSBR Krylene® Emulsion styrene-butadiene rubber E-SBR Krynac® Acrylonitrile-butadiene rubber NBR Krynol® Emulsion styrene-butadiene rubber E-SBR Levamelt Ethylene-vinyl acetate rubber EVM Levapren® Ethylene-vinyl acetate rubber EVM Perbunan® NT Acrylonitrile-butadiene rubber NBR Polysar® S Styrene-butadiene rubber SBR Taktene® Black masterbatches BR Taktene® Butadiene rubber for plastic modification BR Taktene® Butadiene rubber BR Therban® Hydrogenated acrylonitrile-butadiene rubber HNBR
Polyurethanes
The Polyurethanes Business Group (PU) is the world's leading supplier of polyurethane raw materials and systems. The development of new products and technologies, along with intensive customer support in all regions of the world, is an integral element of PU's strategy for success. Regional business service centers strengthen our ties to customers and accelerate business processes.
We offer our customers a comprehensive service package that includes expertise in the processing of polyurethane systems and in the design and functional performance of polyurethane products. The broad spectrum of applications for Bayer polyurethanes stretches from solid materials to foams with a wide range of properties.
Coatings and Colorants
This business group consolidates all products used as raw materials in coatings, sealants and adhesives and as colorants for plastics and construction materials.Environmental compatibility is at the forefront in the development of new products such as high-grade, high-solids and aqueous binders.
Fibers
Established in 1994 in Dormagen, Germany, Bayer Faser GmbH is one of the leading fiber manufacturers in the world. Bayer fibers are used in all kinds of products - from clothing through carpets and home furnishings to fishing lines.
2002/7/1 社内体制として発足
2002/10/1 Bayer CropScience AG 独立
2003/4/25 株主総会で分社承認 （上記CropScienceに加え）
Bayer HealthCare AG, Bayer Polymers AG and Bayer Chemicals AG.
Bayer Business Services GmbH, Bayer Technology Services GmbH
and Bayer Industry Services GmbH & Co. OHG.持株会社の下に、４事業会社、３サービス会社体制
2003/4/28 Bayer USA 新組織発表
Bayer CropScience LP, Bayer Chemicals Corporation, Bayer HealthCare LLC,
Bayer Polymers LLC and Bayer Pharmaceuticals Corporation.
Bayer Corporate and Business Services LLC.持株会社の下に、５事業会社、１サービス会社体制
（本社のHealthCareをHealthCareとPharmaceuticalsに分割）2003/10/2 バイエル ヘルスケア社、ケミカルズ社、テクノロジー サービス社が独立
2003/11 中核の化学事業分離 経営資源、医薬などに集中
2004/10 Bayer to retain stake in GE Bayer Silicones (not transfer to Lanxess)
2003/12 Bayer: All subgroups and service companies now separate legal entities
2004/3 NewCo to be named "LANXESS"
「動き出す」という意味のフランス語『lancer』と
「成功」という意味の英語『success』を組み合わせたもの
2002/7/1 Bayer
New Bayer AG structure operational
Aiming for sustainable increase in corporate value / better
placed for strategic options
http://www.bayer.co.jp/bgj/english/newsfiles/news/back-118_e.html
Effective July 1, 2002, the Bayer Group is operating within its new organizational structure. In the future, the four operating subgroups and three service companies ー under the umbrella of a management holding company ー will focus more strongly on their core competencies, making better use of growth opportunities and aiming for a sustainable improvement in performance.
For the moment the new structure only applies internally, with the future legal entities still being run as organizational units of Bayer AG. In October 2002 Bayer CropScience AG will also become legally independent ー with retroactive economic effect from January 1, 2002.
Bayer HealthCare AG, which comprises the Pharmaceuticals, Consumer Care, Diagnostics, Biological Products and Animal Health business groupsBayer CropScience AG, which combines Bayer's crop protection business with the recently acquired Aventis CropScience
Bayer Chemicals AG, which comprises the current Basic and Fine Chemicals and Specialty Products business groups along with subsidiaries H.C. Starck and Wolff Walsrode.
Bayer Polymers AG, which unites the activities of the current Plastics, Rubber, Polyurethanes, and Coatings and Colorants business groups.
* Service companies
Bayer Business Services, Bayer Technology Services and Bayer Industry Services
Consent is given to the Hive-Down
and Transfer Agreements between the Company and Bayer HealthCare AG, Bayer
Polymers AG and Bayer Chemicals AG.
Consent is given to the Hive-Down
and Transfer Agreements between the Company and the service
companies Bayer
Business Services GmbH, Bayer Technology Services GmbH and Bayer
Industry Services GmbH & Co. OHG..
(Bayer USA)
April 28,2003 Bayer USA
Bayer Launches New North American Organization and New Leadership
http://engine.bayernews.com/engine/search.cfm?hera=5B0A5653&zeus=590B
Consistent with the global reorganization, Bayer's U.S. subsidiary, Bayer Corporation, announced its new organizational structure and leadership team for North America. The new organization includes five operating companies and a service company within a management holding structure.
Bayer's new organization in the United States comprises five operating companies: Bayer CropScience LP, Bayer Chemicals Corporation, Bayer HealthCare LLC, Bayer Polymers LLC and Bayer Pharmaceuticals Corporation. Separately, it has also created a service company, Bayer Corporate and Business Services LLC. These six businesses are under the umbrella of the holding company, Bayer Corporation.
バイエル、EQTに子会社の香料メーカー売却完了
http://www.bayer.co.jp/bgj/newsfile/news/back-160_j.html
バイエルは3日、子会社の香料メーカーであるハーマン・アンド・ライマー社（H＆R）をEQTノーザン・ヨーロッパ・プライベート・エクイティ・ファンズ（EQT）に売却したと発表した。さらに近くラインケミー、ポリマーラテックス両社および家庭用殺虫剤事業も売却する予定だという。
October 1, 2002
Portfolio streamlining continues
Bayer divests Haarmann & Reimer
http://www.bayer.co.jp/bgj/english/newsfiles/news/back-124_e.html
Bayer AG, Leverkusen, has sold its non-core Haarmann & Reimer subsidiary to the EQT Northern Europe Private Equity Funds.
October 4, 2002
Bayer plans to sell Rhein
Chemie to Advent
International → 売却取り止め
Transfer scheduled
for November 2002
http://www.press.bayer.com/news/news.nsf/0/31dff9e37a3cc965c1256c48001bb342/$FILE/2002-0298E.pdf
Bayer AG intends to sell its subsidiary Rhein Chemie Rheinau GmbH, Mannheim, Germany, to a group of financial investors advised by Advent International Corporation, Boston, for EUR 215 million, including the assumption of debt.
December 5, 2002 Bayer
Strategic options for Rhein Chemie under review
http://www.bayerchemicals.com/bch/en/press/press_info/news/2002/12/2002-0372.asp
An agreement concluded in October 2002 between a U.S. financial investor and Bayer concerning the sale of Rhein Chemie has been dissolved by common consent of the parties, who were unable to agree on a number of outstanding points. Various strategic options are currently being considered.
March 26, 2003 Financial Times
Bayer to keep Rhein Chemie.After looking for a buyer for 15 months, Bayer AG of Leverkusen, Germany, has decided not to sell its Rhein Chemie Rheinau GmbH subsidiary. A $212 M deal with the US equity form Advent International Corp fell through in Dec 2002.
独バイエル 渦中の医薬継続 「総合化学」維持 道探る 「内向き」志向の改革カギ
独バイエルが高脂血症治療薬「バイコール」の副作用事故で揺れる医薬事業の継続を決めた。事故後の情報開示の遅れも手伝って信用を失ったが、低成長の化学事業だけでは世界大手として生き残れないと判断したからだ。ＢＡＳＦ、ヘキスト（現アベンティス）を加えたかつての「独三大化学」の中で、化学・医薬の両立にこだわる同社の総合路線が問われる。
米で「副作用死者」
労組が売却反対
化学と異なる性格
他メーカー 得意分野に特化
「三大化学」と呼ばれ、独経済の屋台骨だったＢＡＳＦ、バイエル、ヘキスト。だが、総合化学メーカーと呼べる独企業は今やバイエルだけとなった。売上高で世界最大の化学メーカー、ＢＡＳＦは今年３月に投資がかさむ医薬部門を売却し、化学専業に転換した。ヘキストは仏ローヌ・プーランとの合併で生命科学大手のアベンティスに変わった。
October 28, 2002 Bayer
Bayer CropScience AG to sell a range
of products to BASF
Company on track with regulatory divestments
subsequent to acquisition of Aventis CropScience
http://www.bayer.se/bayer/norden.nsf/0/ab1f574c3bed83adc1256c61002dbf6d?OpenDocument
Bayer CropScience AG today announced that it intends to sell a package of selected insecticides and fungicides to BASF AG while retaining certain back-licenses for non-agricultural applications.With the completion of the envisaged transaction, Bayer CropScience would fulfill within the given timeframe a major condition imposed by the European Commission and the U.S. Federal Trade Commission (FTC) as part of the Aventis CropScience acquisition.
バイエル、ポリマ－ラテックス社の売却決る
バイエルは6日、デグサ社との折半出資会社であるポリマーラテックス社（本社:ドイツ）を金融投資会社のソロス・プライベートエクイティ・パートナーズ社に売却すると発表した。
2003/3/4 Bayer
Bayer and Degussa
sell PolymerLatex to Soros Private Equity Partners
http://www.bayer.se/bayer/norden.nsf/0/25aa9919a04ef2d9c1256d390030727f?OpenDocument
Bayer AG of Leverkusen, Germany, and Degussa AG of Dusseldorf, Germany, are selling PolymerLatex GmbH & Co. KG, their Marl, Germany-based 50:50 joint venture, to the financial investment company Soros Private Equity Partners. The sales price amounts to approx. 235 million euros. The transaction is subject to the approval of the relevant antitrust authorities.The divestments included the subsidiary Haarmann & Reimer, the 30 percent interest in Agfa, a large proportion of the Bayer company apartments, the generics business in France and Spain and the household insecticide business.
日本のバイエル、組織改革進む
バイエル ケミカルズ ジャパン株式会社を７月１日に設立
バイエルグループ、世界および日本における化学品事業を更に強化
http://www.bayer.co.jp/bgj/newsfile/news/news-183_j.html
基礎・精密化学品およびスペシャリティ製品等の化学製品を取り扱う事業部門を新設分割の方法により、全額出資子会社としてバイエル ケミカルズ ジャパン株式会社を設立する。
今回の組織改革は、バイエルグループが世界規模で推進している戦略的な４事業部門の再編の一環として実施される。
China Chemical
Reporter 2003/7/29
Bayer Plans to
Invest in the Construction of a HDI Project in Shanghai
Bayer of Germany has signed with Shanghai Chemical Industry Development Zone an MOU on the construction of a 30 000 - 50 000 t/a HDI (hexamethylene diisocyanate) project in the next 3 years.
August 11, 2003 Bayer
Polymers
Asian center for high performance coating raw materials
Bayer Polymers plans large-scale investments at its Caojing,
China, site
http://www.news.bayer.com/news/news.nsf/0/3F930E8DDDAF0B1FC1256D7F003A05B7?Open&ccm=010005000&l=EN
Bayer Polymers, a division of Bayer AG, plans to expand its Caojing site near Shanghai, China, making it Bayer Polymers' most important production facility for coating raw materials in the Asia Pacific region. Production plants for aliphatic (脂肪族) and aromatic polyisocyanates as well as the monomer hexamethylene diisocyanate (HDI) will be constructed in three phases at the Shanghai Chemical Industry Park.
2003年10月2日 バイエル株式会社
バイエルグループの組織再編進む
バイエル ヘルスケア社、バイエル
ケミカルズ社、バイエル テクノロジー
サービス社が独立
http://www.bayer.co.jp/bgj/newsfile/news/news-190_j.html
日本経済新聞 2003/11/8
発表
独バイエル 中核の化学事業分離 経営資源、医薬などに集中
独バイエルは７日、ポリマーと化学事業部門を再編して新会社を設立し、２００５年初めまでに株式上場させると発表した。化学部門の各種中間剤や繊維・製紙化学製品などをポリマー部門と統合し、新会社をつくる。中核の化学事業を分離独立させ、バイエル本体は医薬や農業化学など開発投資がかさむ事業に経営資源を集中する。
Werner Wenning continues
systematic realignment:
Bayer plans stock
market flotation for chemicals activities and strategic refocus
of health care business
http://www.press.bayer.com/News/News.nsf/id/0029E5ECD27BC2F7C1256DD70043DABF
Supervisory Board
approves Management Board plans /
Focus on core
businesses should enhance Bayer's competitiveness /
New company to be
positioned among Europe's leading chemical enterprises /
Pharmaceuticals
business to be retained as stand-alone solution
Following its
successful reorganization, the Bayer Group intends to maintain
its focus on its core businesses and in the future concentrate on
health care, nutrition and innovative materials. For this reason, Bayer
Chemicals (excluding H.C. Starck and Wolff Walsrode) is to be
combined with certain parts of the polymers business in a new
company with the provisional name "NewCo".
Media briefing on November 26,
2003, Shanghai, China
http://www.news.bayer.com/News/News.nsf/id/29E09CD16BF08DC6C1256DE90037A77C
H.C.Starck Metallic and Ceramic Powders
Refractory Metal Parts and Components, Heavy Metal / Tungsten Alloy
Electronic Chemicals, Functional Materials
Engineered Parts of Advanced Ceramics
October 22, 2004 Financial Times
Bayer to retain stake in GE Bayer Silicones.
In early 2005, Lanxess AG will be spun off from Bayer and will supply chemicals, plastics and rubber. Originally, it was planned to include the 49% stake in GE Bayer Silicones GmbH and Co KG held by Bayer, but the company has now decided to retain this. The spin off will be covered at the Bayer shareholders' meeting on 17 Nov 2004. .
http://www.sap.com/industries/chemicals/pdf/CS_GE_Bayer_Silicones.pdf
GE Bayer Silicones evolved out of the merger in 1998 between the silicones division of Bayer AG and General Electric Silicones Europe. As a result, the Leverkusen, Germany-based company is now one of the leading producers of silicone products in Europe, with production sites throughout Germany, the Netherlands, the U.K., and India. Together with its parent company, Bayer AG, and its sister companies, GE Silicones in the United States and GE Toshiba Silicones in Japan, GE Bayer Silicones forms a global alliance that ensures a market presence anywhere in the world.
2003/12/15 Bayer
バイエル、約22億ユーロの減損費用を計上
キャッシュフローと配当支払い能力には影響なし
http://www.news.bayer.com/News/News.nsf/id/2003-0592
バイエル（本社：ドイツ、レバクーゼン、社長：ヴェルナー・ヴェニング）は、2003年第4四半期（2003年9月～12月）に合計22億ユーロの資産減損費用(asset impairment
charges) を計上することになった。この費用は、製品群の戦略的な再編、分社化が決定した新会社（化学品事業と一部の高分子材料事業より構成）の株式上場計画、並びに今後のバイエル
マテリアルサイエンス事業グループの経営条件の変化と関係している。なお、金利・税金支払い前収益（EBIT）へのこれら特別項目の影響は約20億ユーロになると予想されており、営業外収益は約2億ユーロ減少する見込み。
高分子、化学品事業における資産減損費用 17億ユーロ
バイエル
ヘルスケア事業グループは 約5億ユーロ
December 11, 2003
Bayer
Bayer and DuPont
expand leading position in engineering thermoplastics
Dedication of
world-scale plant for the production of polybutylene
terephthalate (PBT)
Operator is
the joint venture DuBay Polymer GmbH / Total investment 50
million euros / Annual capacity: 80,000 tons
http://www.news.bayer.com/News/News.nsf/id/2003-0589
With the dedication of a
world-scale plant for the production of polybutylene
terephthalate (PBT)
in Hamm-Uentrop, Germany, Bayer and DuPont are building on their
position as leading manufacturers of engineering thermoplastics.
With an initial capacity of 80,000 tons per year, the plant is the biggest of its
kind in the world. It will be operated by DuBay Polymer
GmbH, a joint venture between Bayer and DuPont. The two companies have together
invested some 50 million euros in the plant, in which 61 people
are employed.
March 22, 2004
Bayer CropScience
Bayer CropScience to purchase Crompton's share of Gustafson seed
treatment business
Acquisition for 124 million US Dollar in North America and Mexico
http://www.bayercropscience.com/bayer/cropscience/cscms.nsf/id/D50F9538CF30D718C1256E5F0052372E?Open&ccm=400190000&L=EN&markedcolor=%23003399
Bayer CropScience LP in the U.S. and Bayer CropScience Inc. in Canada today signed agreements to purchase Crompton Corporation's 50 percent share of the Gustafson seed treatment business in the United States, Canada and Mexico [NAFTA] for the purchase price of U.S.$124 million in cash.
The action would give Bayer CropScience, which already holds a 50 percent share of the U.S. and Canadian Gustafson joint ventures, full ownership of Gustafson's NAFTA business, subject to customary closing conditions. The transaction is expected to close by the end of the first quarter.
May 4, 2004 Bayer
Agreement signed to build a plant for the coating raw material
HDI
Bayer: Investments to strengthen growth in China
http://www.news.bayer.com/News/News.nsf/id/2004-0258
In the presence of
Gerhard Schroder, the German Chancellor, and Wen Jiabao, the
Chinese Premier, Werner Wenning, the Chairman of the Board of
Management of Bayer AG, and Prof. Gottfried Plumpe, a member of
the Board of Management of Bayer MaterialScience AG, signed an
agreement with Ruan Yanhua, President of the Shanghai Chemical
Industry Park Corporation, to build a world-scale production
plant for the coating raw material HDI
(hexamethylene diisocyanate). The ceremony was held during the third
German-Chinese high-technology dialogue forum on May 4, 2004, in
Berlin.
The HDI project involves a total capacity of up to 50,000 t/y and an investment of some USD
100 million. Construction of the new facility is scheduled to
begin in fall 2004.
China Chemical Reporter 2004-10-13
Bayer MaterialScience Builds New Production Facilities in ChinaWith the construction of new production plants for polyurethane and coating raw materials near Shanghai, Bayer MaterialScience AG is all set to increase its long-term competitiveness on the growth market of China. Dr. Hagen Noerenberg, CEO of Bayer MaterialScience, got the two big projects under way in a symbolic ceremony.
By 2006, a production facility for the coating raw material hexamethylene diisocyanate (HDI) and a production plant and logistics facilities for the polyurethane raw material diphenylmethane diisocyanate (MDI) will be built in the Shanghai Chemical Industry Park in Caojing. Bayer MaterialScience is the number one market player for both isocyanate coating raw materials and polyurethane raw materials. The two projects represent a total investment of around US$ 200 million.
July 19, 2004 Bayer
Bayer to Acquire Roche Consumer Health
http://www.news.bayer.com/News/News.nsf/id/2004-0448
Acquisition creates global
consumer health care company that will rank among top three
worldwide / Acquisition price EUR 2.380 billion including U.S. joint
venture
With the acquisition of Roche Consumer Health, Bayer is going to
extend its portfolio of long-standing brands for commercial
success.
Bayer announced today that it has agreed to acquire Roche
Consumer Health. By acquiring this business Bayer will become one
of the top three over-the-counter (OTC) consumer health companies
worldwide. Additionally, Bayer will acquire Roche's 50 percent
share of the 1997 Bayer/Roche joint venture in the U.S., (an element not included in Roche's
original offering) and five Roche production sites in Grenzach
(Germany), Gaillard (France), Pilar (Argentina), Casablanca
(Morocco) and Jakarta (Indonesia). The OTC business of the Japanese company
Chugai, in which Roche has a majority stake, is not included. The acquired business has yearly sales of
around EUR 1 billion. The EUR 2.380 billion transaction is
subject to approval by relevant antitrust authorities.
Roche and Bayer to form an OTC
joint venture in the United States
http://www.roche.com/media-news-1996-09-16-e.pdf
Roche Holding Ltd., Basel,
Switzerland and the US subsidiary of Bayer AG, Leverkusen,
Germany, have entered into a letter of intent to form a 50-50
joint venture to market several over-the-counter (OTC) drugs in
the United States.
Subject to the approval of the relevant authorities, the joint
venture will combine the companies' US OTC businesses in
analgesics (except for Bayer Aspirin) and women's health. Brands
included in the joint venture will be Roche's Aleve analgesic and
Femstat 3 vaginal yeast infection treatment and Bayer's Actron
and Vanquish analgesics, Midol menstrual pain reliever and
Mycelex-7 vaginal yeast infection treatment.
Bayer will be responsible for sales and marketing of the joint
venture products within its overall Consumer Care portfolio.
2004/09/13 Bayer
バイエル社とシェリング・プラウ社、医療用医薬品事業で戦略的業務提携に合意
http://release.nikkei.co.jp/detail.cfm?relID=81176
■米国と日本でマーケティング・販売の業務提携を締結
■米国の医療用医薬品事業のポジショニングを修正
■がん領域における世界的な事業部を設立
バイエル社は、同社ヘルスケア事業（バイエルヘルスケア社）の組織的再編を引き続き行い、米国に本拠を置くシェリング・プラウ社（本社：ニュージャージー州ケニルワース）と医療用医薬品事業に関する広範な業務提携を締結したことを本日発表しました。この合意内容に基づき、米国でのバイエル社のプライマリーケア製品（主にかかりつけ医で最初の治療として処方される薬剤）は、シェリング・プラウ社がマーケティングおよび販売を行ないます。
この合意内容に基づき、シェリング・プラウ社は米国およびプエルトリコにおけるバイエル社のプライマリーケア製品のマーケティングおよび販売を担当し、米国におけるバイエル社のマーケティングおよび販売組織の大部分はシェリング・プラウ社に統合されます。シェリング・プラウ社の増強された営業組織による情報提供活動は、季節的な活動量の変動にも柔軟に対応することが可能で、バイエル製品のポテンシャルを大きく引き出します。
この発表と同時に、バイエル社は世界市場を担うがん領域の事業部を新たに設立し、その営業組織を構築します。このがん領域事業部はコネチカット州ウエスト・ヘブンに本部を置き、オニックスファーマシューティカル社と共同開発中の抗がん剤ＢＡＹ ４３－９００６の承認取得および発売の準備を行います。進行性腎細胞がんの治療薬として臨床試験で有望な結果を示しているこの開発候補品は、現在第ＩＩＩ相臨床試験が行われています（日本国内では第Ｉ相臨床試験）。
2004/12/13 バイエル
バイエル社、血漿分画製剤事業を米国投資会社
Cerberus社とAmpersand社に売却
http://release.nikkei.co.jp/detail.cfm?relID=88770&lindID=4
－コージネイト®は、バイエル ヘルスケア社の製品として継続販売－
「血漿分画製剤事業の売却は、バイエルヘルスケア社のビジネス再構築を進める上で重要なステップです。バイエル社はこれまで以上に、コンシューマー向けヘルスケア製品、人と動物向けの画期的医薬品と高性能診断機器のビジネスに注力します。バイエル社が行ったロシュ社一般用医薬品事業の買収とシェリング・プラウ社との医療用医薬品事業提携は、この新たな戦略的再編を強調するものです」とバイエル社社長ヴェルナー・ヴェニングは述べています。
本契約の内容には、バイエル ヘルスケア社バイオロジカルプロダクト事業部の血漿分画製剤事業に関連する製品、施設そして社員が含まれています。血友病Ａの治療に使用される遺伝子組換え型血液凝固第ＶＩＩＩ因子製剤コージネイト®は売却対象ではなく、バイエル ヘルスケア社の製品としてこれまでどおりに販売されます。
【 Cerberus Capital Management, L. P.社について 】
Cerberus Capital Management, L. P.社は、ニューヨークに拠点を置く１９９２年創立の民間投資会社で、１４０億ドル超える投資資産を管理しています。Ｃｅｒｂｅｒｕｓ社は、北米、欧州、アジアでの事業を含む、様々なビジネス分野において４０社以上の経営権を保有しています。Ｃｅｒｂｅｒｕｓ社は、資産価値を重視する投資会社で、長期に渡る高収益力の業績を求め、自社とのパートナーシップによる収益性を追求します。
【 Ampersand Ventures社について 】
Ampersand Ventures社は、Panie Webber社から分離した１９８８年創立の民間の株式投資会社で、積極的な事業提携を通じて資産価値の増やすことに注力しています。Ａｍｐｅｒｓａｎｄ社は、広範囲の技術産業の分野に渡って独自の投資戦略を追求します。会社の資産の大半は、売却会社、拡大融資、中規模の企業買収そして業績回復のための資本再構成のポートフォリオに投資されます。Ampersand社は、１９９５年から血液製剤事業積極的な投資を行っており、現在バイエル社へ血漿分画工程業務を行っているPrecision
Pharma Services社の経営権を保有しています。
October 11, 2004
People's Daily
Shanghai aims to
become world-class isocyanate production base
Construction of
Germany-based Bayer's major chemical projects began here Monday,
which industry sources see will accelerate Shanghai's efforts to
build a world-class isocyanate production base.
The two projects are
part of Bayer's 3.1-billion-US dollar investment for establishing
a major production base in Shanghai.
Isocyanate, also known as MDI/TDI, is the
main chemical material for producing polyurethane, which is
widely used in the production of electronic and electric
appliances, construction materials, automobiles, packing
materials, furniture, shoes, sealant, heat-isolation and
refrigerant agents.
Bayer launched a polyisocyanate factory in Shanghai in early
2001, which went into operation two years later. It was Bayer's
first project for its base in Shanghai and one of the major parts
of Shanghai's chemical production base. Currently, the factory
has received orders for polyisocyanate that already fill up its
production plan for 2005.
Isocyanate and
polyurethane are engineering plastics that witness the fastest
growth in both production and demand in the world. China's demand
for the two products grows at an annual rate of 12 percent and 10
percent respectively, while its production lags far behind
demand.
Besides Bayer, other
two world's chemical giants, BASF and Huntsman, also have
investment in Shanghai.
Sources from Bayer
said the company has expanded its designed annual production
capacity of polycarbonate in Shanghai from 50,000 tons to 200,000
tons and establish China's largest polycarbonate installation in
Shanghai.
バイエル、日本において市場成長率を上回る発展に注力
－2005年1-9月期の売上は7.8%増の1,490億円
－2008年までに1億3,000万ユーロ以上を投資
http://www.bayer.co.jp/bgj/newsfile/news/news-248_j.html
バイエルグループ（本社：ドイツレバクーゼン、代表取締役社長：ヴェルナー・ヴェニング）は、日本においてさらなる発展を目指しており、2008年までに1億3,000万ユーロ以上を日本に投資する計画である。
バイエル、上海近郊の新生産基地に関する基本契約に調印
中国に31億ドルを投資
http://www.bayer.co.jp/bgj/newsfile/news/back-108_j.html
世界的なヘルスケア・化学グループであるバイエル（本社：ドイツ・レバクーゼン）は、中国における事業拡大のため、このほど中国・ソウケイ（Caojing）（上海近郊）の新生産基地に関する基本契約に調印した。総投資額は31億ドル（34億ユーロ）。
各プロジェクトの概要
第１号プロジェクト
ソウケイ（Caojing）のバイエル新生産基地の第1号プロジェクトは、自動車、建設、家具業界で使用される塗料・着色材の製造である。バイエルは2008
年までに計1億1,000万ドル（1億2,200万ユーロ）を投資する。建設の第1段階では、ポリイソシアネートの生産施設（年産1万1,500トン）が建設される。操業開始は2003年の予定。その後、生産能力は年産2万トンに引き上げられる見込み。建設の第2段階では、原料となるHDIの生産ユニットも建設される。バイエルの100％子会社「バイエル塗料システムズ（上海）社」が2000年12月に事業免許を取得しており、このプロジェクトの運営にあたる。
第２号プロジェクト
ソウケイ（Caojing）の第2号プロジェクトは、バイエルのポリカーボネート「マクロロン」の世界規模の生産施設である。これは塗料生産施設と歩調を合わせて建設される。高機能ポリカーボネート「マクロロン」は、例えばCDやDVDなどの光学記憶システムに使用されるが、他にも電子、建設、自動車産業にも広範な用途がある。バイエルの合弁相手である上海クロルアルカリ社と協力して、バイエルは年産10万トンのポリカーボネート生産コンビナートを建設する予定である。
年産5万トンの生産能力を持つ当初の生産ラインが2003年に操業を開始し、2006年にはフル稼働する。当プロジェクトの総投資額は4億5,000万ドル（5億ユーロ）で、原料となるビスフェノールＡの生産施設と配合工場が含まれている。
このプロジェクトは、バイエルの新しい子会社「バイエル・ポリマー（上海）社」（バイエルが株式の90％、上海クロルアルカリ社が10％を保有）が運営にあたる。プロジェクトの事業免許は2001年9月に承認されている。
建設は2001年11月2日に開始する。
第３号プロジェクト
ソウケイ（Caojing）の第3の主要プロジェクトは、ポリウレタン原料の大規模生産施設である。多様な用途を持つポリウレタンは、軟質・硬質のフォームとして、特に家具、自動車、建設産業で多様な用途を有するほか、冷凍・冷蔵機器やスポーツ・娯楽産業の製品でも使用されている。
このプロジェクトは、バイエルの新しい100％子会社「バイエル・ポリウレタン（上海）社」の名称で運営される。総投資額は約11億ドル（12億ユーロ）で、年産38万トンのイソシアン酸塩工場が建設される。このうち
23万トンはMDI、15万トンはTDIである。ポリウレタン生産では、イソシアン酸塩に続いてポリオールが2番目に重要な生産品目である。ポリエーテルの生産量は年産28万トンの予定。
2001年8月、中国の国家発展計画委員会は、バイエルのポリウレタン生産施設の主要プロジェクトを承認した。バイエルは、2005年までに最初のポリウレタン工場の操業開始を目標としている。
追加プロジェクトの見通し
これらの3つの主要プロジェクトに加えて、追加のプロジェクト（複数）と土地借り入れの総投資額が14億ドル（15億5,000万ユーロ）に上るため、ソウケイ（Caojing）の総投資額は31億ドル（34億ユーロ）となる。プロジェクトには、高機能樹脂、その他の原料、基礎化学品の生産施設が含まれる。
Bayer May 15, 2006
Bayer MaterialScience develops pioneering technology for the
production of TDI
http://www.baynews.bayer.de/BayNews/BayNews.nsf/id/2006-0267-e
High-output and resource-saving production process / Significantly reduced investment and operating costs / First use on a world scale at the integrated production site in Caojing
Bayer MaterialScience AG
has developed a pioneering technology for
producing toluene diisocyanate (TDI), which reduces the investment
costs involved in constructing production plants by 10 to 20
percent. Moreover, the technology reduces the energy consumption
by one third and sets new safety standards. A pilot plant with an
annual production capacity of 30,000 tons has been in operation
in the Bayer Chemical Park in Dormagen for over a year. The new
technology is scheduled to be used for the first time on a world
scale at Bayer MaterialScience’s Caojing site near Shanghai. The company plans
to construct a fully integrated TDI production plant there with
an annual capacity of 160,000 tons by the end of 2009. TDI is used
worldwide for the production of flexible polyurethane foam, large
quantities of which are used in upholstered furniture, mattresses
and automotive seating.
In the summer of 2005, Bayer MaterialScience finished years of
work on a consolidation process for TDI and its primary products
and has since focused its production on integrated world-scale
plants. The story is similar with methylene diphenyl diisocyanate
(MDI), an important raw material for producing rigid polyurethane
foam, which guarantees a highly efficient insulation effect.
Bayer MaterialScience is currently constructing a world-scale
production plant for MDI in Caojing with a capacity of
350,000 tons a year, which
is due to commence operation in 2008. The inauguration of a
splitter for recovering monomeric and polymeric MDI from crude
MDI is already scheduled for fall of this year. It will boast an
annual capacity of 80,000 tons.
September 5, 2006
Bayer
Bayer CEO Wenning at the inauguration of new production
facilities in Shanghai
“China
is of central importance to Bayer”
Total capital
expenditures of US$ 1.8 billion at the Shanghai Chemical Industry
Park through 2009
Significant capacity expansions for polycarbonates, polyurethanes
and coating raw materials
Bayer’s largest capital expenditure
project outside Germany
In these respects the company expects the new production
facilities to play a key role. Dr. Jurgen Dahmer - Senior Bayer
Representative for Greater China and Senior Representative for
Bayer MaterialScience in China, and thus “landlord”
of the Shanghai
site - presented the details of these plans in his welcoming
address. The existing facilities will now be supplemented by
- a world-scale polycarbonate production unit with
a starting capacity of 100,000 tons per year,
- the first polyurethane facility at the Bayer site - a crude MDI
(diphenylmethane diisocyanate) splitter with a capacity of 80,000
tons per year and
- a production unit for HDI (hexamethylene diisocyanate)
with an initial capacity of 30,000 tons per year.
The Asia-Pacific region is the biggest market for polycarbonate
in terms of volume, with 1.5 million tons sold last
year, more than half the world market of 2.7 million tons. Of this volume, Greater China
alone accounts for 650,000 tons, with consumption growing at
around 18 percent a year.
Polyurethane raw materials are a further focus of production at
the site. These MDI-based intermediates are used in the
production of rigid foam for thermal insulation, among other
applications. The inaugurated facility - a “splitter”
that separates crude MDI into monomeric and polymeric MDI
- is just the beginning. A large-scale MDI production facility
with a capacity of 350,000 tons per year, due on stream in 2008,
will be the largest of its kind in the world. Also planned is a
production facility for the intermediate TDI (toluene diisocyanate), which is
used to manufacture flexible foams for applications such as car
seats, mattresses and furniture. With a capacity of 160,000 tons per year, this plant is expected
to come on stream in 2009.
Bayer began its production activities at the site in 2003 with
coating raw materials, for which capacity currently is 22,500
tons per year. The company will now be able to produce another 30,000 tons of
the raw material HDI,
with the option of expanding this capacity by a further 20,000
tons. Polyurethane-based coatings today offer the best
performance spectrum. They are used, for example, on the Lupu
Bridge - Shanghai’s most famous landmark - or in
high-tech automotive coatings to provide long-term protection
against weathering.
Since April 2003 Bayer has been producing Desmodur® N coating raw materials in Caojing with an annual capacity of 11,500t; by the end of 2004, a production plant for Desmodur® L is due to go on stream with a capacity of 11,000t/yr.
Bayer's Desmodur® L, N and Mondur® MR and MRS are polyisocyanate raw materials which, when used in combination with our polyether polyols (Acclaim®, Multranol® and Arcol®), produce reactive adhesives.
October 23, 2006 Bayer
Bayer MaterialScience to acquire Taiwan’s Ure-Tech Group （台湾優得）
New global leader
in thermoplastic polyurethane resins and films
Bayer MaterialScience will acquire Taiwan’s Ure-Tech Group, the largest
thermoplastic polyurethane (TPU) producer in the Asia Pacific
region. With
this acquisition the Germany-based company will become the worldwide
largest supplier and solutions provider of TPU resins and films. The deal is subject to regulatory
approval by the cartel office and is expected to be closed in the
first quarter of 2007. Both parties have agreed not to disclose
purchase price and other related details of the acquisition. In
2005, approximately 180 employees of the Ure-Tech Group generated
sales of around USD 55 million. Sales of Bayer MaterialScience’s Business Unit Thermoplastic
Polyurethanes amounted to 192 million Euros last year with
roughly 450 employees.
TAIWAN URE-TECH CO.,LTD. was found in May 1992. Head office is located in Chang Hwa Coast Industrial Park in Chang Hwa, Taiwan. We are a professional manufacturer of Thermoplastic Polyurethane (TPU) elastomer. The
commercial name of products is "Utechllan(R)". Office in Shenzhen, China was established in Oct. 1998. In order to serve the local customers, we have established XUDE 旭得 RUBBER (SHENZHEN) CO.,LTD. and manufactured products since Sep.2002.
http://www.uretech.com.tw/eng/eng_company_profile.htm
Auction process
successfully concluded:Bayer sells H.C. Starck to Advent
International and The Carlyle Group for EUR 1.2 billion
Proceeds will help to finance the Schering acquisition /
Acquirers plan expansion of H.C. Starck business /
Goal is to position the company for an initial public offering in
3 to 5 years
The Bayer Group plans to sell its subsidiary H.C. Starck to a
consortium formed by financial investors Advent
International and The Carlyle Group for approximately EUR 1.2
billion. As planned, the proceeds will help to finance the
acquisition of Schering. Commenting on the transaction,
Bayer Management Board Chairman Werner Wenning said: “We are convinced that H.C. Starck
will have very good development prospects under the new owners.”
The transaction
value comprises a cash component of more than EUR 700 million and
the assumption of financial liabilities and personnel-related
commitments totaling some EUR 450 million. The divestment thus
reduces Bayer’s net debt by about EUR 1 billion,
with an accounting gain of about EUR 150 million. Closing is
planned to take place at the beginning of 2007, subject to the
approval of the antitrust authorities.
Bayer conducted the sale of H.C. Starck as an auction
process.
Several of the many prospective acquirers were invited to examine
the company in detail and submit a binding offer. Both strategic
and financial investors participated in the bidding through the
final stage.
H.C. Starck, headquartered in Goslar in northern Germany,
manufactures metal and ceramic powders,
specialty chemicals,
and parts made from advanced ceramics and refractory metals. The
company employs some 3,400 people and last year posted sales of
EUR 920 million. H.C. Starck has 15 sites in Europe, Asia and
North America.
Bayer announced in March 2006 that it would divest its
subsidiaries H.C. Starck and Wolff
Walsrode
and use the proceeds to partly finance the Schering acquisition.
The two companies have so far been part of the Bayer
MaterialScience subgroup, which will focus in future on
its core businesses.
About Advent International:
Advent International is one of the world’s leading private equity firms,
with over EUR 8 billion (US$ 10 billion) in cumulative capital
raised and offices in 14 countries across Western and Central
Europe, North America, Latin America and Asia. Since its
inception in 1984, Advent has invested in more than 500 companies
in 35 countries and has taken over 130 of these businesses public
on major stock exchanges worldwide. Advent has a proven track
record of success in the German market, having concluded eight
transactions in the past two years. In 2004, for example, Advent
and Carlyle jointly acquired HT Troplast, the world’s leading manufacturer of vinyl
profiles for windows and doors.
(bought Vinnolit GmbH & Co. KG)
About The Carlyle Group:
The Carlyle Group is a global private equity firm with more than
US$ 46 billion (EUR 36 billion) under management. Carlyle invests
in buyouts, venture and growth capital, real estate and leveraged
finance in North America, Europe and Asia. Focus industries are
aerospace, automotive & transportation, consumer &
retail, chemicals, energy & power, healthcare, industrial,
technology & business services, and telecom & media.
Since 1987, Carlyle has invested total equity capital of US$24
billion (EUR 19 billion) in 576 transactions.
H.C. Starck is an international group of companies with more than 3,400 employees at 14 production sites in Europe, North America and the Far East. 非鉄金属及び希少金属・化合物・セラミックス粉末等の分野で世界に名高いメーカーであるドイツ・スタルク社
H.C. Starck produces an assortment of refractory metal powders that is unique the world over, including tungsten, molybdenum, tantalum, niobium, rhenium as well as their compounds (borides, carbides, nitrides, oxides, silicides, sulfides). A further production focus centers on thermal spray and advanced ceramic powders, nonferrous metals, such as nickel and nickel salts, as well as boron and boron compounds.
In addition to metal powders, semi-finished and finished molybdenum, tungsten, tantalum, niobium, titanium, zirconium and nickel products and their alloys are manufactured. Further to the production of standard components, H.C. Starck is your partner for the manufacture of components according to customers' specifications. Our experts provide answers and solutions to your challenges and problems in all areas ranging from construction to alloying, especially for customized components. As a further service H.C. Starck offers the extrusion of molybdenum and TZM.
H.C. Starck is also a leading supplier of specialty chemicals and products formulated for the electronics industry.
In the engineering ceramics sector H.C. Starck has a wide assortment of ceramic intermediates. Its subsidiary H.C. Starck Ceramics GmbH & Co. KG manufactures machine and engine components, anti-friction bearing components and foundry products made of silicon carbide, silicon nitride, aluminum titanate as well as zirconium and aluminum oxide according to customers' specifications. The H.C. Starck Ceramics R&D laboratory also conducts material tests and process developments for customers.
H.C. Starck became a member of the Bayer Group in 1986 and maintains certified Quality Management Systems at all of its sites. Many locations also have Environment Management Systems.
日本法人 スタルク 株式会社 (H.C. Starck Ltd.)
設立 1986年2月4日
事業目的
1. コンデンサ用タンタル粉末の製造
2. コンデンサ用タンタル粉末、ワイヤー、炉材の販売
3. 超硬工具用及びサーメット・セラミックス工具用各種炭化物、複合炭化物、窒化物、ホウ化物材料、セラミックス焼結晶の販売
4. 超電導材用ニオブアロイ及び金属ニオブの販売
5. 電気・電子・光学用各種酸化物の販売
6. コンデンサ・帯電防止用チオフェン系導電性高分子材、ＣＭＰスラリー用コロイダルシリカの販売
7. 触媒・顔料・電池用の金属粉末、酸化物、水酸化物及び固体潤滑剤等の販売
8. タンタル、モリブデン、タングステン等のワイヤー、シート、箔、棒材、インゴット、その他焼結品及び粉末の販売
9. その他金属・合金及び化合物加工品の販売
沿 革
1986年2月4日
ファンスティール社(米国)と株式会社ヴイ・テックの出資により、株式会社ヴイ・テック-ファンスティールを設立
1989年9月1日
株式会社ヴイ・テックと合併
1990年2月15日
H.C.スタルク社が大株主になり、商号を株式会社ヴイ・テックに変更
1993年1月1日
スタルク ジャパン株式会社と合併し、商号をスタルク ヴイテック株式会社 に変更、
2004年11月30日
全株式をH.Cスタルク社からバイエル株式会社へ譲渡
2005年10月1日
商号をスタルク株式会社へ変更
With its almost 200-year history, the Wolff Walsrode AG is one of Bayer's most traditional production sites. As a holding company, Wolff Walsrode operates the Competence Center for cellulose chemistry and markets the Walsrode Industrial Park (which is now open to outside companies), one of the most highly regarded economic locations in Lower Saxony.
The company has transferred its operations to the independent companies Wolff Cellulosics and CaseTech and the technical service provider Probis. It is particularly strong in the field of cellulose derivatives and services such as engineering, utilities, technical service, logistics, waste management and environmental protection, supporting Bayer Material Science in many key entrepreneurial functions. In this capacity, it makes a vital contribution to enabling its parent company to successfully assert itself as an innovative manufacturer. The CEO of Wolff Walsrode, Dr. Dieter Herzog, has no doubts whatsoever: "We play an important role within the Bayer MaterialScience group and are the driver for technological progress in the field of cellulose chemistry."
Our everyday life would be inconceivable without cellulose derivatives, which are used in a vast number of different products. They serve as thickeners in building materials such as tile adhesives, plasters and emulsion paints and also in foodstuffs, cosmetics and pharmaceuticals, and as binders in printing inks and surface coatings.
With its 1,270 employees, the Wolff Walsrode company posted sales last year of around EUR 329 million.
Bayer
2006/12/7
Bayer MaterialScience Expands Production Network in Asia
World’s biggest
global polycarbonate supplier
provides fast local service / Additional EUR 80 million invested
in China and India
As demand for Makrolon(R) continues to rise, Bayer
MaterialScience AG is steadily increasing polycarbonate
production around the world. And at the end of 2006, the company
will be producing 1,200,000 tons of Makrolon a year.
Additional international spending of around EUR 80 million is to
be invested to build up a network in Asia in the next few years,
allowing the company to offer excellent technical service locally
and supply customers quickly and flexibly. The investments will
be used, for example, to build additional
compounding plants in China and India.
Furthermore, a Color Competence Center (CCC) is to be
built at the compounding plant in
Shanghai, which has been in production since
2005. Combined with the Polymer Research and Development Center
in Pudong, Shanghai, the region will become an important center
for Asian and Chinese customers.
Baytown (United States) 260 kt Antwerp (Belgium) 240 kt Uerdingen (Germany) 330 kt Map Ta Phut (Thailand) 270 kt Shanghai 100 kt total 1,200 kt
Bayer December 12,
2006
Bayer MaterialScience expands MDI production capacity in
Tarragona to 150,000 tons a year
Location is key component of global production network
Bayer MaterialScience AG has now completed the expansion of its
production facilities for methylene diphenyl diisocyanate
(MDI) in Tarragona, Spain by 50,000 tons a year to an annual
capacity of 150,000 tons. As a result, the company has a
global production capacity of almost 1.1 million tons per year.
Plant capacity at Tarragona for the intermediates carbon monoxide
(CO) and methylene diphenyl diamine (MDA) has also been expanded.
MDI production facilities in Krefeld-Uerdingen
(Germany) were also expanded in summer 2006 by 36,000 tons to a
capacity of 200,000 tons a year. At its integrated Shanghai site, Bayer MaterialScience is
currently building world-scale production facilities capable of
producing 350,000 tons of MDI each year. The facilities are to
start operating in 2008 and will mainly supply customers in the
Asia-Pacific region. A splitter used to extract monomeric and
polymeric MDI from crude MDI that has a plant capacity of 80,000
tons a year went into operation there in June 2006. Bayer
MaterialScience also operates production facilities for MDI in Brunsbuttel
(Germany), Baytown and New Martinsville (both United States),
Belford Roxo (Brazil) and Niihama (Japan).
| October
11, 2006 |
|
| Bayer
MaterialScience closes MDI Facility at New Martinsville,
W.Va., USA |
 |
| The methylene
diphenyl isocyanate (MDI) facility at the Bayer
MaterialScience plant in New Martinsville, W.Va., with an
annual design capacity of 160 million pounds (approx.
73kt), will close on June 30, 2007. Approximately 230
positions will be affected by the closure. “The economies of scale are changing in the MDI marketplace, and Bayer is consolidating production to several world-scale plants, including its plant in Baytown, Texas,” said Jim Covington, New Martinsville General Plant Manager. To better serve our Northeastern U.S. customers, New Martinsville will continue to be an MDI, TDI and HCL transloading and distribution center, sourcing material from our Baytown plant. |
February 7, 2007
Bayer
First facility of its kind in China:Bayer establishes APAC spray
competency center in Shanghai
Strong growth for composite materials in China
Bayer MaterialScience has set up a spray competency
center in
Shanghai, China, to demonstrate its expertise in polyurethane
spray technology in the Asia Pacific region. It features
state-of-the-art processes and technologies for reinforced and
un-reinforced systems. The spray competency center, located
within Bayer MaterialScience’s Polymer Research &
Development Center (PRDC) in Shanghai, is one of three regional
facilities established globally by Bayer MaterialScience.
In addition to the Baytec(R) Reactive polyurethane
system, a
thick, high quality film coating used to waterproof buildings and
to protect bridges, truck beds and other large structured parts
against corrosion, the spray center also features Bayer
MaterialScience’s Multitec(R) and
Baypreg(R) polyurethane spray technologies.
Bayer 2007/2/6
Bayer MaterialScience intends to expand annual capacity of TDI
production facility in Shanghai to 300,000 tons
Innovative production technology means much lower costs
Bayer MaterialScience AG intends to boost the annual capacity of
the planned plant for producing toluene
diisocyanate (TDI) in Shanghai from 160,000 to 300,000 tons.
Bayer MaterialScience expects its newly developed TDI process
technology to cut investment costs by some 20
percent
compared with conventional processes. The process - known as gas phase
phosgenation -
has already been successfully trialed in a company pilot plant
with an annual capacity of 30,000 tons.
The new technology for TDI production developed by Bayer MaterialScience is to be used at the plant it is building at Caojing near Shanghai in China to increase its capacity from the planned 160,000 tonnes to 300,000 tonnes. The gas phase phosgenation process reduces investment costs by 20 per cent and energy costs by 40 per cent. It also increases safety and reduces the use of solvents.
Bayer CropScience agrees
to acquire US cotton seed company Stoneville for US-$ 310 million
Acquisition of leading US cotton
business expected to bolster growth strategy
Bayer CropScience
announced today that it has entered into an agreement to purchase Stoneville
Pedigreed Seed Company, a leading US provider of cotton
seeds, from Monsanto Company for a total purchase price of
US-$ 310 million (approximately EUR 230 million). The agreement
was signed on May 31, 2007. This acquisition is expected to
enhance the fast-growing US cotton seed business of Bayer
CropScience, currently the second largest cotton seed supplier in
North America. The acquisition is subject to the approval of the
US competition authorities.
Bayer keen on consumer health buys
Bayer AG is keen on further acquisitions of over-the-counter medicines as part of a strategy to balance "volatility" within its larger prescription drugs business, its head of healthcare said on Thursday.
But he aims to balance this by also growing the more stable consumer health operation, adding that there were no plans for rationalising the overall business.
Within healthcare, Higgins said he wanted to see prescription pharmaceuticals remaining at no more than 60-70 per cent of the total, which he acknowledged was likely to require additional scaling up of consumer products.
He noted Bayer had already proved itself a leader in consolidating the non-prescription drugs industry by acquiring Roche Holding AG's OTC drugs business.
Bayer in spotlight after Sabic's GE Plastics buy
Bayer AG Chief Executive
Werner Wenning has always said the company's
plastics business is an important part of the drugs and chemicals
conglomerate.
But for investors, the question is for how long?
But it highlights the question of how the plastics business fits
with the rest of the group as Bayer transforms
itself into a healthcare player following its $23 billion
purchase of Schering AG last year.
"The only thing that doesn't fit
from the logic point of view to a life science company is Bayer
Material Science,"
said Boris Schakowski, a fund manager at Union Investment.
Last year, the material
science unit accounted for 35 percent of group sales, down from
38 percent a year ago, while those from the healthcare unit --
with only a partial contribution from Schering -- rose to 40
percent from 32 percent.
Profit margins at the materials unit also fell.
Analysts at Citigroup forecast the unit's core margin will
decline to 13.4 percent this year and to 11.7 percent next year
from 18.7 percent in 2005.
By contrast, in the healthcare unit UBS analysts anticipate its
profit margin rising to 25 percent in 2008 from 19 percent in
2005.
Bayer MaterialScience to
build up a world-scale plant for polymer polyols using a new
technology
Commissioning scheduled in 2008 /
Forward-looking production process
delivers optimized products /
Significantly lower energy costs
In close cooperation with Bayer Technology Services GmbH, Bayer MaterialScience AG has developed an innovative technology for the manufacture of polymer-filled polyether polyols that delivers significantly better products than the conventional process. The innovative technology has already been successfully tested on a multi-ton scale in a technical service laboratory. The new process is to be used on a world scale for the first time in a PMPO（polymer polyol ） production facility with an annual capacity of 60,000 tons. It is due to be commissioned at the end of 2008 and shall be constructed either in Dormagen, Germany, or in Antwerp, Belgium. At both sites, Bayer MaterialScience already manufactures polyether polyols, one of the basic components required to produce polymer
